<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446586</url>
  </required_header>
  <id_info>
    <org_study_id>Tyrosinemia Registry E&amp;AW 1</org_study_id>
    <nct_id>NCT03446586</nct_id>
  </id_info>
  <brief_title>Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)</brief_title>
  <official_title>Hereditary Hepatorenal Tyrosinemia Natural History (Multicenter Clinical Study): Registry for Patients With Tyrosinemia Type I in Egypt and the Arab World</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yassin Abdelghaffar Charity Center for Liver Disease and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Friends of Liver Patients in the Arab World (SLPAW)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yassin Abdelghaffar Charity Center for Liver Disease and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the registry/repository is to understand the natural history of tyrosinemia in
      our region and to provide a mechanism to store data and specimens to support the conduct of
      future research about hereditary tyrosinemia among the Arabs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to create an electronic registry of phenotypic, laboratory
      information, treatment and outcomes options for tyrosinemia type I. The registry is
      longitudinal in nature including retrospective clinical data from birth to the most recent
      encounter with all data entered in chronological fashion. The goals of this registry are the
      better understanding of the natural history and treatment outcomes of these patients and to
      determine/evaluate biochemical and clinical parameters for monitoring and prognosis of
      tyrosinemia type I.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2, 2018</start_date>
  <completion_date type="Anticipated">June 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Create a registry for tyrosinemia type I.</measure>
    <time_frame>5 Years</time_frame>
    <description>This outcome is a binary 'yes/no' outcome as to whether or not this study can successfully create a repository with the intent to store data and specimens to support the conduct of future research on tyrosinemia type I.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hereditary Tyrosinemia, Type I</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fixed liver block samples &amp; frozen whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tyrosinemia type I seen by one of the participating sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biochemical or molecular diagnosis of Tyrosinemia Type I.

          2. Examined/followed by one of the participating sites.

          3. Parental/guardian permission (informed consent) for participation.

        Exclusion Criteria:

          1. Diagnosis of tyrosinemia has been excluded.

          2. Not examined/followed by one of the participating sites.

          3. Unwilling to provide informed consent for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawhida Y Abdelghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yassin Abdelghaffar Charity Center for Liver Disease and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mamdouh A. Ahmed</last_name>
    <phone>02-01221707770</phone>
    <email>dr.yassinabdelghaffar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research</name>
      <address>
        <city>Nasr City</city>
        <state>Cairo</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamdouh A. Ahmed</last_name>
      <phone>02-01221707770</phone>
      <email>dr.yassinabdelghaffar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tawhida Y. Abdel Ghaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yassin Abdelghaffar Charity Center for Liver Disease and Research</investigator_affiliation>
    <investigator_full_name>Dr. Tawhida Yassin Abdel Ghaffar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tyrosinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

